Table 1. Main characteristics and safety outcomes of the selected studies.
| Trial | Treatment arm | Number of patients | TRAEs G3-5, n | Discontinuation, n |
|---|---|---|---|---|
| KEYNOTE-024 | Pembrolizumab vs. platinum-based CT | 154 vs. 151 | 48/154 vs. 80/150 | 21/154 vs. 16/150 |
| KEYNOTE-042 | Pembrolizumab vs. platinum-based CT | 637 vs. 637 | 117/636 vs. 253/615 | 62/636 vs. 59/615 |
| IMpower-110 | Atezolizumab vs. platinum-based CT | 286 vs. 286 | 37/286 vs. 117/263 | 18/286 vs. 43/263 |
| CheckMate-227 Part 1 | Nivolumab vs. platinum-based CT | 396 vs. 397 | 76/391 vs. 141/387 | 28/391 vs. 11/387 |
| MYSTIC | Durvalumab vs. platinum-based CT | 374 vs. 372 | 56/369 vs. 122/352 | 20/369 vs. 33/352 |
| EMPOWER-Lung 1 | Cemiplimab vs. platinum-based CT | 355 vs. 342 | 50/355 vs. 134/342 | 52/355 vs. 39/342 |
| KEYNOTE-189 | Pembrolizumab + platinum-pemetrexed vs. platinum-pemetrexed | 410 vs. 206 | 196/405 vs. 80/202 | 85/405 vs. 17/202 |
| KEYNOTE-407 | Pembrolizumab + carboplatin + (nab-)paclitaxel vs. carboplatin + (nab-)paclitaxel | 278 vs. 281 | 152/278 vs. 154/280 | 50/278 vs. 20/280 |
| IMpower-150 arm B vs. arm C | Bevacizumab + atezolizumab + carboplatin + paclitaxel vs. bevacizumab + carboplatin + paclitaxel | 400 vs. 400 | 201/393 vs. 181/394 | 133/393 vs. 98/394 |
| IMpower-130 | Atezolizumab + carboplatin + nab-paclitaxel vs. carboplatin + nab-paclitaxel | 483 vs. 240 | 354/473 vs. 141/232 | 125/473 vs. 51/232 |
| IMpower-132 | Atezolizumab + platinum-pemetrexed vs. platinum-pemetrexed | 292 vs. 286 | 167/291 vs. 114/274 | 69/291 vs. 48/274 |
| IMpower-131 | Atezolizumab + carboplatin + nab-paclitaxel vs. carboplatin + nab-paclitaxel | 343 vs. 340 | 231/334 vs. 195/334 | 102/334 vs. 58/334 |
| CheckMate-227 Part 2 | Nivolumab + platinum-based CT vs. platinum-based CT | 377 vs. 378 | 45/375 vs. 35/371 | 30/375 vs. 11/371 |
| CheckMate-9LA | Nivolumab + ipilimumab + CT vs. platinum-based CT | 358 vs. 349 | 171/358 vs. 123/349 | 68/358 vs. 25/349 |
| CheckMate-227 Part 1 | Nivolumab + ipilimumab vs. platinum-based CT | 583 vs. 583 | 189/576 vs. 205/570 | 104/576 vs. 52/570 |
| MYSTIC | Durvalumab + tremelimumab vs. platinum-based CT | 372 vs. 372 | 88/371 vs. 122/352 | 49/351 vs. 33/352 |
TRAEs, treatment-related adverse events; G, grade; n, number.